The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis

Y Huang, W Hong, X Wei - Journal of hematology & oncology, 2022 - Springer
Epithelial–mesenchymal transition (EMT) is an essential process in normal embryonic
development and tissue regeneration. However, aberrant reactivation of EMT is associated …

Linking EMT programmes to normal and neoplastic epithelial stem cells

AW Lambert, RA Weinberg - Nature Reviews Cancer, 2021 - nature.com
Epithelial stem cells serve critical physiological functions in the generation, maintenance
and repair of diverse tissues through their ability to self-renew and spawn more specialized …

Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis

S Usman, NH Waseem, TKN Nguyen, S Mohsin… - Cancers, 2021 - mdpi.com
Simple Summary Vimentin is an important filamentous protein providing structural and
functional support to the cell. During initial stages of cancer development, vimentin …

Mechanisms of cancer metastasis

M Castaneda, P den Hollander, NA Kuburich… - Seminars in cancer …, 2022 - Elsevier
Metastatic cancer is almost always terminal, and more than 90% of cancer deaths result from
metastatic disease. Combating cancer metastasis and post-therapeutic recurrence …

CD44 as a tumor biomarker and therapeutic target

H Xu, M Niu, X Yuan, K Wu, A Liu - Experimental hematology & oncology, 2020 - Springer
CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including
the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple …

EMT transition states during tumor progression and metastasis

I Pastushenko, C Blanpain - Trends in cell biology, 2019 - cell.com
Epithelial–mesenchymal transition (EMT) is a process in which epithelial cells acquire
mesenchymal features. In cancer, EMT is associated with tumor initiation, invasion …

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

KGK Deepak, R Vempati, GP Nagaraju… - Pharmacological …, 2020 - Elsevier
Triple negative breast cancer (TNBC) is most aggressive subtype of breast cancers with high
probability of metastasis as well as lack of specific targets and targeted therapeutics. TNBC …

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

T Shibue, RA Weinberg - Nature reviews Clinical oncology, 2017 - nature.com
The success of anticancer therapy is usually limited by the development of drug resistance.
Such acquired resistance is driven, in part, by intratumoural heterogeneity—that is, the …

Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment

B Wu, X Shi, M Jiang, H Liu - Molecular Cancer, 2023 - Springer
Ongoing research has revealed that the existence of cancer stem cells (CSCs) is one of the
biggest obstacles in the current cancer therapy. CSCs make an influential function in tumor …

A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer

V Jain, H Kumar, HV Anod, P Chand, NV Gupta… - Journal of Controlled …, 2020 - Elsevier
Breast cancer (BC) is one of the most prevalent cancers in women. Triple-negative breast
cancer (TNBC) in which the three major receptors ie estrogen receptor (ER), progesterone …